Category Archives: Events

Latest From Events

Pearls of Wisdom for Getting the Most out of the 2011 BIO International Convention

Recently the Oklahoma Bioscience Association held a 2011 BIO International Convention information session for their delegates to get ready for the June event. BIO’s own Margaret Core participated via video conference, where she gave an overview of the convention. There were three other speakers who shared their advice based on their BIO experiences.  The panelists were: Dr. Paul DeAngelis, Chief Scientist, Hyalose LLC and Professor. Dept. of Biochemistry & Molecular Biology, University of Oklahoma Health Read More >

Events  |  Leave a comment  |  Email This Post
Tags: ,

BIO Europe Spring – State of the Biotech Industry

BIO Industry Analysis provided opening remarks at BIO Europe Spring in Milan, Italy, this morning.  Dr. John Craighead shared the highlights of BIO’s latest industry update: click here for the slides in pdf format.

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2011, The Year of Positive Thinking? BIO/IPREO Study Reveals High Hopes for the Industry

BIO CEO’s closing plenary session featured plenty of crystal ball gazing and candid quips about what 2011 has in store for the biotech industry.  While the panel provided an in-depth look at how buy-side and sell-side analysts evaluate the industry, the BIO/IPREO Investor Perception Study reveals that the majority of investors believe biotech is headed in the right direction.  Access full study deck here: BIO CEO – IPREO Biotech Investor Perception Study The study also reveals that Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Release of BIO/Biomedtracker Drug Approval Rates Study

BIO and BioMedTracker are pleased to present the findings of their joint clinical trial success rates study.  Using clinical trial data from the past seven years, this analysis examines the most recent probability of success by treatment type, phase of development and therapeutic area. The overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is near one in 10, not one in five to one Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

State of the Industry – From BIO Investor Forum 2010

Here is our slide deck from the 9th annual BIO Investor Forum in San Francisco: BIO Investor Forum 2010 final   From the media and blogosphere: Bloomberg in vivo blog Medical Technology Stock Letter

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,